Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.
Visualization of neurotransmission components in living small animals using positron emission tomography (PET) has the potential of contributing to the preclinical development of neuroactive drugs, although it is yet to be examined whether quantitative animal PET data on candidate compounds can be extrapolated to humans. Here, we investigated the comparability of the occupancies of serotonin transporter (5-HTT) by therapeutic agents in rat PET studies with our predetermined data from ex- vivo animal experiments and clinical PET scans. Rats were treated with varying doses of fluvoxamine and a newly developed compound, (2S)-1-[4-(3,4-dichlorophenyl) piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol monohydrochloride (Wf-516), and underwent PET scans with [11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile ([11C]DASB), a selective radioligand for in-vivo quantification of 5-HTT. PET images indicated a reduction of [11C]DASB binding to 5-HTT as a function of the doses and/or plasma concentrations of fluvoxamine and Wf-516. The doses of these drugs at half-maximal effect (15.2 mg/kg and 3.1 mg/kg, respectively), determined that using binding potentials for [11C]DASB, were comparable to those estimated by our previous ex-vivo measurements in rats (4.5 mg/kg and 1.1 mg/kg, respectively), as there was only a 3-fold difference between these results. Moreover, the plasma concentration of fluvoxamine needed for 50% occupancy of central 5-HTT (6.1 ng/ml) was almost equivalent to the value determined in human PET studies (4.6 ng/ml). These findings support the view that the conjunctive use of small-animal PET and [11C]DASB facilitates a quantitative comparison of in-development drugs targeting 5-HTT with established inhibitors and a predictive estimation of their plasma concentrations exerting therapeutic effects in humans.
Saijo
Takeaki
T
Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.
Maeda
Jun
J
Okauchi
Takashi
T
Maeda
Jun-Ichi
J
Morio
Yasunori
Y
Kuwahara
Yasuhiro
Y
Suzuki
Masayuki
M
Goto
Nobuharu
N
Suzuki
Kazutoshi
K
Higuchi
Makoto
M
Suhara
Tetsuya
T
D018685:Anesthetics, Inhalation / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000097:blood / Q000494:pharmacology*; D001596:Benzylamines / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D001931:Brain Mapping; D002247:Carbon Isotopes / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016666:Fluvoxamine / Q000097:blood / Q000494:pharmacology*; D007530:Isoflurane / Q000494:pharmacology; D008297:Male; D010069:Oxadiazoles / Q000097:blood / Q000494:pharmacology*; D010880:Piperidines / Q000097:blood / Q000494:pharmacology*; D049268:Positron-Emission Tomography / Q000379:methods*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D013997:Time Factors; D014851:Wakefulness / Q000187:drug effects
D018685:Anesthetics, Inhalation; D000928:Antidepressive Agents; D001596:Benzylamines; D002247:Carbon Isotopes; C420885:N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine; D010069:Oxadiazoles; D010880:Piperidines; D050486:Serotonin Plasma Membrane Transport Proteins; C527744:Wf-516; D007530:Isoflurane; D016666:Fluvoxamine